February 6, 2020

Stability Law 2020: news about homeopathic medicines

Stability Law 2020 (Law No. 160 of December 27, 2019) extended the period for homeopathic medicines available on the Italian market on June 6, 1995 to remain on the market, subject to the regulation provided by Article 20 of the Pharmaceutical Code (Legislative Decree No. 219 of April 24, 2006) and Article 1 (590) of Law No. 190 of December 23, 2014.

On the one hand, Stability Law 2020 clarified that companies that had applied for renewal of marketing authorization (MA) by June 30, 2017 will be able to keep the relevant products on the market until the outcome of Italian Medicines Agency (AIFA) assessments are known. Those assessments are taking a considerable amount of time due to the large number of products submitted for consideration. On the other hand, Stability Law 2020 set a peremptory deadline for the marketing of homeopathic medicines on the market on January 1, 2020 that are not subject to renewal procedures.

Specifically, Article 1 (464) of Stability Law 2020 provides as follows:

  • that a homeopathic medicine (i) already on the Italian market on June 6, 1995 and (ii) subject to an MA renewal procedure filed with AIFA by June 30, 2017 will be kept on the market until the assessment carried out by AIFA is completed;
  • that a homeopathic medicine (i) already on the Italian market on June 6, 1995, (ii) not subject to an MA renewal procedure filed by June 30, 2017, and (iii) present in the distribution channel on January 1, 2020 shall be kept on the market until the expiration date of the medicine indicated on its label, but no later than January 1, 2022.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Follow us on
Follow us on